Wikipedia: Glucagon-like peptide-1 receptor agonist
Encyclopedia overview of the GLP-1 RA drug class—history, approved indications, representative molecules, and links to outcome trials; tertiary navigation only.
Scope vs this protocol
Centers incretin-mimetic pharmacotherapy (native GLP-1 receptor agonists and related regulatory threads). Dual GIP/GLP-1 agents appear in the same consumer/regulatory conversation—trial endpoints still belong to PubMed-linked rows on glp-1-receptor-agonist-therapy.
Evidence discipline
Use for class definitions, timelines, and outbound citations—MACE trials, HbA1c deltas, and wearable autonomic numbers must be read from PubMed-linked sources here (e.g., Marso et al. 2016 LEADER for liraglutide MACE; Grosicki et al. 2025 for 12-week telemetry).
Pairing
Read next to intermittent fasting / time-restricted eating only to contrast behavioral versus pharmacologic weight-metabolism levers—do not merge evidence streams.
Outcomes
- Tertiary map: class-level indication and safety vocabulary—quantitative cardiovascular and glycemic outcomes require linked primary literature on this wiki.